Canaccord Genuity Maintains Buy on Nektar Therapeutics, Lowers Price Target to $149

Benzinga · 2d ago
Canaccord Genuity analyst Edward Nash maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and lowers the price target from $153 to $149.